Trial Profile
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Bausch Health Companies; Ortho Dermatologics
- 09 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 09 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 07 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.